|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.490 USD | -7.68% |
|
-12.42% | -19.28% |
| Jun. 13 | Moderna falls on doubts over new CDC panel's backing of RSV vaccine | RE |
| Jun. 12 | Novavax: positive results for Covid/flu vaccine | CF |
| Capitalization | 1.05B 912M 856M 779M 1.43B 90.76B 1.62B 10B 3.9B 41.47B 3.94B 3.86B 153B | P/E ratio 2025 * |
2.54x | P/E ratio 2026 * | 20.7x |
|---|---|---|---|---|---|
| Enterprise value | 672M 583M 547M 498M 914M 58.04B 1.03B 6.39B 2.49B 26.52B 2.52B 2.47B 97.53B | EV / Sales 2025 * |
0.66x | EV / Sales 2026 * | 1.53x |
| Free-Float |
94.79% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Novavax, Inc.
More recommendations
More press releases
More news
| 1 day | -7.68% | ||
| 1 week | -12.42% | ||
| Current month | -11.58% | ||
| 1 month | -3.57% | ||
| 3 months | -22.55% | ||
| 6 months | -29.69% | ||
| Current year | -19.28% |
| 1 week | 6.46 |  | 7.8 |
| 1 month | 6.46 | | 8.78 |
| Current year | 5.01 | | 11.55 |
| 1 year | 5.01 | | 17.81 |
| 3 years | 3.53 | | 76.77 |
| 5 years | 3.53 | | 331.68 |
| 10 years | 3.53 | | 331.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Jacobs
CEO | Chief Executive Officer | 58 | 2023-01-22 |
James Kelly
DFI | Director of Finance/CFO | 59 | 2021-08-15 |
John Trizzino
DFI | Director of Finance/CFO | 65 | 2021-04-11 |
| Director | Title | Age | Since |
|---|---|---|---|
Richard Douglas
BRD | Director/Board Member | 72 | 2010-08-05 |
Rachel King
BRD | Director/Board Member | 65 | 2018-10-31 |
David Mott
BRD | Director/Board Member | 59 | 2020-06-15 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.31% | 21 M€ | +0.81% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -7.68% | -12.42% | -53.81% | -82.77% | 1.05B | ||
| -0.20% | -2.91% | +18.40% | +14.81% | 48.55B | ||
| +30.00% | +363.16% | +72,525.70% | +6,614.30% | 38.57B | ||
| -3.23% | -0.03% | -27.76% | -21.56% | 26.66B | ||
| +0.62% | +3.17% | -3.66% | +20.89% | 26.1B | ||
| +0.23% | +3.83% | +15.51% | -20.34% | 12.55B | ||
| -2.62% | +4.74% | +92.19% | - | 12.14B | ||
| -3.52% | +1.54% | -55.16% | -28.10% | 11.27B | ||
| -2.71% | -0.14% | +38.78% | +119.97% | 10.44B | ||
| -1.90% | +0.82% | +3.49% | +0.83% | 10.08B | ||
| Average | -1.93% | +37.79% | +7,255.37% | +735.34% | 19.74B | |
| Weighted average by Cap. | -0.99% | +73.84% | +14,175.13% | +1,383.86% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.02B 887M 833M 758M 1.39B 88.31B 1.57B 9.73B 3.8B 40.35B 3.84B 3.76B 148B | 527M 458M 429M 391M 717M 45.53B 811M 5.01B 1.96B 20.8B 1.98B 1.94B 76.5B |
| Net income | 494M 429M 402M 366M 672M 42.66B 760M 4.7B 1.83B 19.49B 1.85B 1.81B 71.69B | 60.4M 52.41M 49.19M 44.74M 82.12M 5.22B 92.88M 574M 224M 2.38B 227M 222M 8.76B |
| Net Debt | -379M -329M -309M -281M -515M -32.72B -583M -3.6B -1.41B -14.95B -1.42B -1.39B -54.99B | -246M -213M -200M -182M -334M -21.24B -378M -2.34B -913M -9.7B -923M -904M -35.69B |
More financial data
* Estimated data
Employees
952
Calendar
Jun. 20
- Annual General Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-17 | 6.490 $ | -7.68% | 8,763,585 |
| 25-06-16 | 7.030 $ | +1.30% | 4,590,283 |
| 25-06-13 | 6.940 $ | -2.94% | 5,179,634 |
| 25-06-12 | 7.150 $ | +0.85% | 4,000,736 |
| 25-06-11 | 7.090 $ | -1.53% | 5,975,769 |
Delayed Quote Nasdaq, June 17, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
6.490USD
Average target price
13.43USD
Spread / Average Target
+106.91%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NVAX Stock
Select your edition
All financial news and data tailored to specific country editions
